Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

BACKGROUND: We analyzed the 96-week results in the overall population and in prespecified subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients. METHODS: Eligible patients with HIV-1 RNA (vRNA) levels >5000 copies per milliliter and without baseline resistance to efav...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Acquir Immune Defic Syndr
Main Authors: Lennox, Jeffrey L., DeJesus, Edwin, Berger, Daniel S., Lazzarin, Adriano, Pollard, Richard B., Madruga, Jose Valdez Ramalho, Zhao, Jing, Wan, Hong, Gilbert, Christopher L., Teppler, Hedy, Rodgers, Anthony J., Barnard, Richard J. O., Miller, Michael D., DiNubile, Mark J., Nguyen, Bach-Yen, Leavitt, Randi, Sklar, Peter
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6065510/
https://ncbi.nlm.nih.gov/pubmed/20404738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e3181da1287
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki